+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma



Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma



Dermatologic Surgery 32(1): 63-69



Curettage and electrodesiccation (C&D) is a widely used method to treat nodular basal cell carcinoma (BCC). However, residual tumor is present immediately after the procedure in approximately 20 to 40% of cases. Imiquimod, a topical immune response modifier that targets Toll-like receptor 7, is currently approved for superficial BCC. In a double-blind, vehicle-controlled study, the administration of imiquimod after C&D was investigated to determine if the combination regimen would reduce the frequency of residual tumor compared with C&D alone in patients with nodular BCC. Twenty patients received three cycles of C&D followed by imiquimod 5% or vehicle cream once daily for 1 month as adjunctive therapy. The primary end point was the frequency of residual tumor. The secondary end points included the time to heal and cosmetic appearance. Twenty patients were randomized to the imiquimod (n = 10) or vehicle (n = 10) treatment group. At 8 weeks, the proportion of patients with residual tumor was substantially decreased with imiquimod therapy (10%) compared with vehicle (40%). Wounds in the vehicle group healed more quickly than those in the imiquimod group, although by 8 weeks, all excision sites were healed. The majority of scars in the control group were atrophic and hypopigmented, whereas most scars in the imiquimod group were flat and slightly pink. Imiquimod 5% cream once daily for 1 month as adjunctive therapy after C&D substantially reduced the frequency of residual tumor and improved the cosmetic appearance compared with C&D alone. These preliminary results suggest that further studies to investigate imiquimod adjunctive therapy are warranted.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 049929919

Download citation: RISBibTeXText

PMID: 16393600

DOI: 10.1111/1524-4725.2006.32007


Related references

Imiquimod 5% cream following curettage without electrodesiccation for basal cell carcinoma: preliminary report. Journal of Drugs in Dermatology 7(1 Suppl 1): S15-S16, 2008

An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australasian Journal of Dermatology 47(1): 46-48, 2006

Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage. Journal of Drugs in Dermatology 6(9): 910-914, 2007

Imiquimod 5% Cream as Adjunctive Therapy For Primary, Solitary, Nodular Nasal Basal Cell Carcinomas Before Mohs Micrographic Surgery. Dermatologic Surgery 35(1): 24-29, 2009

A retrospective study on the effectiveness of curettage and electrodesiccation for clinically suspected primary nodular basal cell carcinoma. British Journal of Dermatology 175(5): 1097-1098, 2016

Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study. Dermatologic Surgery 35(1): 24-29, 2009

Imiquimod 5% Cream as Adjunctive Therapy for Primary, Solitary, Nodular Nasal Basal Cell Carcinomas Before Mohs Micrographic Surgery: A Randomized, Double Blind, Vehicle-Controlled Study. Yearbook of Dermatology and Dermatologic Surgery 2010: 348-349, 2010

Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream. Dermatology Online Journal 14(2): 25, 2008

Treatment of Basal cell carcinoma with curettage followed by imiquimod 3.75% cream. Journal of Clinical and Aesthetic Dermatology 4(5): 39-43, 2011

A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma. Journal of Drugs in Dermatology 7(1 Suppl 1): S7, 2008

Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. American Journal of Ophthalmology 140(6): 1136-1139, 2005

Immunotherapy With Imiquimod 5% Cream for Eyelid Nodular Basal Cell Carcinoma. Yearbook of Ophthalmology 2007: 231-232, 2007

Case study: Imiquimod 5% cream in the treatment of a large nodular basal cell carcinoma. Dermatology Nursing 21(2): 86-87, 2009

Ulcerated nodular nasal basal cell carcinoma successfully treated with imiquimod 5% cream. Journal of Drugs in Dermatology 10(3): 240-241, 2011

Resolution of tinea pedis with imiquimod cream 5% in a patient with nodular basal cell carcinoma. Cutis 78(1): 66-69, 2006